India built its pharmaceutical industry on generics — making the world’s medicines affordable. Now the patent data tells a different story. From 1,186 filings in 2000 to 18,668 in 2024, a country that once reverse-engineered drugs is increasingly inventing them.
In 2000, India’s pharmaceutical patent office recorded 1,186 filings. By 2007, that number had climbed to 7,466 — a six-fold increase driven largely by multinational companies filing in India ahead of the 2005 TRIPS compliance deadline, when India amended its patent law to recognize product patents for the first time.
Then the numbers plateaued. For nearly a decade, from 2007 to 2020, annual filings hovered between 5,000 and 7,200. The optimists had predicted an explosion of domestic innovation after TRIPS. The skeptics had predicted a freeze. Neither was quite right: what actually happened was a slow build.
The explosion came later. In 2021, filings jumped to 8,729. In 2022, they nearly doubled to 14,369. By 2024, the count reached 18,668 — a 161% increase over the 2014 baseline. The partial 2025 data already shows 15,485 filings, suggesting the full year will match or exceed 2024. Something structural changed.
The data divides cleanly into three periods. The first, from 2000 to 2005, was the pre-TRIPS rush: multinationals racing to file in India before the patent regime changed. Filings quadrupled from 1,186 to 4,488 in five years, driven almost entirely by foreign applicants protecting existing portfolios.
The second era, from 2006 to 2020, was the long plateau. Annual filings fluctuated between 4,400 and 7,500, never breaking decisively higher. This was the period when India’s generics industry was at its most productive — supplying 20% of the world’s generic medicines by volume — but patent filings barely grew. The business model didn’t require invention; it required process excellence.
The third era began in 2021. Filings surged past 8,000 and kept climbing: 14,369 in 2022, 16,733 in 2023, 18,668 in 2024. The composition shifted too. Indian companies that had spent decades building manufacturing scale began filing patents on novel drug delivery systems, biosimilar processes, and combination therapies. The generics machine was still running. But something new was being built on top of it.
Among the 25 OPPI member companies — the multinational pharma firms with India operations — Roche leads with 1,888 filings, followed by Bayer (1,865), Novartis (1,816), and Johnson & Johnson (1,512). These four companies alone account for over 7,000 filings in India’s patent system.
The grant rate tells a different story. Of Bayer’s 1,865 filings, 224 have been granted — a 12% success rate. Roche’s 1,888 filings yielded 189 grants (10%). Novartis, despite being the third-largest filer, has only 123 grants (6.8%). India’s Section 3(d) — the provision that bars patents on new forms of known substances unless they demonstrate enhanced therapeutic efficacy — remains the gatekeeper. The bar is high. It is meant to be.
Of the 187,353 pharmaceutical patent applications filed in India, 19,462 have been granted — an overall rate of 10.4%. This is not a sign of dysfunction. It is the result of a patent regime designed to be selective.
India’s 2005 patent amendments introduced Section 3(d), which specifically excludes new forms, new uses, and new combinations of known substances unless they show significantly enhanced efficacy. The provision was tested most famously in the 2013 Novartis v. Union of India case, where the Supreme Court upheld the rejection of a patent on the beta crystalline form of imatinib (Glivec). The decision sent a clear signal: India would grant pharmaceutical patents, but only for genuine innovation.
The numbers bear this out. Early filings (pre-2005) have much higher grant rates — 100% for the handful filed in 1994, declining to 67% by 2000 as volume grew. Post-2005 filings show grant rates between 2% and 10%, reflecting both the stricter standard and the backlog at the patent office. The 2017 cohort is an outlier: 1,717 grants from 5,287 filings (32%), likely reflecting a clearance of older applications.
India’s pharmaceutical exports have grown from $14 billion to $31 billion in twelve years. The industry and government target is $50 billion. Reaching it will require not just manufacturing volume but intellectual property — novel molecules, biosimilar platforms, and drug delivery systems that command higher margins than commodity generics.
The patent data suggests the transition is underway. The question is whether the pace is fast enough. India’s share of global pharmaceutical R&D spending remains in the low single digits. Its patent filings, while surging domestically, are still a fraction of what the United States, China, or the European Patent Office process annually.
But the direction is unmistakable. A country that built its pharmaceutical reputation on making other people’s drugs cheaper is now, increasingly, making its own.